It will receive neuromuscular electrical stimulation addition to the designed physical therapy program, 3 times per week for 6 weeks.

It will receive task-oriented training, in addition to receiving a designed physical therapy program, 3 times per week for 6 weeks.

It will receive neuromuscular electrical stimulation with task-oriented training in addition to the designed physical therapy program, 3 times per week for 6 weeks.

Surface electrodes will be applied over the motor points of the supraspinatus and deltoid muscles on the paretic side, as well as over the wrist extensors on the dorsal forearm. Electrical stimulation will be delivered using a symmetrical biphasic waveform at a frequency of 30 Hz and a pulse width of 300 μs, with ramp-up and ramp-down times of 1 second each. The current intensity will be adjusted to the patient's maximum tolerance, up to 90 mA. The intervention will be administered for 30 minutes, three times per week, over a period of 6 weeks using the Gymna 400 Series device, with patients positioned in sitting, while participants in Group 2 will not receive electrical stimulation.

The FMA-UE will be used to assess upper limb motor impairment in stroke patients. It consists of 33 items evaluating reflex activity, movement synergies, coordination, sensation, and joint range of motion of the affected limb. Each item is scored on a 3-point scale (0-2), with a maximum score of 66 indicating full motor recovery. The assessment takes approximately 30 minutes and demonstrates high reliability. In this study, it will be applied to the affected upper extremity before and after the intervention.

The ARAT will be used to evaluate upper limb functional performance. It includes four subtests (grasp, grip, pinch, and gross movement) using standardized objects. Patients will be seated with the affected arm supported, and tasks will assess the ability to handle objects of varying sizes and perform functional movements. Each task is scored from 0 to 3, with a maximum score of 57 indicating optimal function. The ARAT provides a comprehensive measure of hand function and dexterity.

The MAS will be used to assess spasticity in the affected upper limb. It is a 6-point ordinal scale ranging from 0 (no increase in muscle tone) to 4 (rigidity in flexion or extension), with 1+ indicating slight resistance through less than half the range. This scale is widely used in stroke populations and has established validity for assessing muscle tone. MAS scores will be recorded before and after treatment.

Kinovea software will be used to analyze upper limb kinematics during functional tasks. It provides valid and reliable measurements of joint angles and distances using video-based motion analysis. In this study, it will assess the range of motion of the shoulder, elbow, and wrist during the reach-and-grasp phase. This tool allows objective quantification of movement quality and coordination.